Back to Awarded Treatment Trials


Awarded Trial: 00-093

Grant ID

00-093

Illness

Schizophrenia

Primary Drug/Intervention

Cannabidiol

Primary Dosage

up to 800g/day

Secondary Drug Intervention

Amilsupiride

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Leweke

Sample Size

70

Duration of Study Period for Each Subject

4 weeks

Outcome Measurements

8PRS, PANSS

Results

Thirty-nine patients completed the four-week trial, or the two-week period necessary for data analysis. Both amisulpiride and cannabidiol produced significant reductions in positive, negative and general symptoms. Cannabidiol did not cause extrapyramidal side effects, weight gain, or prolactin elevation.

Publication

Transl Psychiatry. 2012 Mar 20;2:e94. doi: 10.1038/tp.2012.15. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Leweke FM1, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterk├Âtter J, Hellmich M, Koethe D.

Link

http://www.ncbi.nlm.nih.gov/pubmed/22832859

PI Name

Franz-Markus Leweke

Degree

MD

Center

Department of Psychiatry and Psychotherapy

Institution

Klinikum der Unversitaet zu Koeln

Address

Kerpener Str. 62

City or Town

Koeln

State or Province

N/A

Zip or Postal Code

50937

Country

Germany

Email Address

m.leweke@uni.de